VCYT's Afirma and Decipher fuel strong test volume growth and a debt-free balance sheet, but rising macro costs and expenses temper the outlook.

This collaboration has broad implications for biopharma and precision medicine. Researchers will be able to generate causal data, clinicians will be able to access new functional maps for interpreting ...